miR-146a is directly regulated by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumor immune suppression

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians 2010; 60:277-300; PMID:20610543; http://dx.doi.org/10.1017/S000983880999067X
   PubMed Web of Science ®Google Scholar
• Lasaro MO, Ertl HC. Targeting inhibitory pathways in cancer immunotherapy. Curr Opin Immunol 2010; 22:385-90; PMID:20466529; http://dx.doi.org/10.1016/j.coi.2010.04.005
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19851315; http://dx.doi.org/10.1038/nrc2734
   PubMed Web of Science ®Google Scholar
• Sun X, Sui Q, Zhang C, Tian Z, Zhang J. Targeting blockage of STAT3 in hepatocellular carcinoma cells augments NK cell functions via reverse hepatocellular carcinoma-induced immune suppression. Mol Cancer Ther 2013; 12:2885-96; PMID:24107450; http://dx.doi.org/10.1158/1535-7163.MCT-12-1087
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mule J, Kerr WG, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11:1314-21; PMID:16288283; http://dx.doi.org/10.1038/nm1325
   PubMed Web of Science ®Google Scholar
• Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006; 203:1651-6; PMID:16801397; http://dx.doi.org/10.1084/jem.20051848
   PubMed Web of Science ®Google Scholar
• Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10:48-54; PMID:14702634; http://dx.doi.org/10.1038/nm976
   PubMed Web of Science ®Google Scholar
• Su JC, Tseng PH, Hsu CY, Tai WT, Huang JW, Ko CH, Lin MW, Liu CY, Chen KF, Shiau CW. RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget 2014; 5:4909-19; PMID:24952874
   PubMed Web of Science ®Google Scholar
• Wang J, Yin D, Xie C, Zheng T, Liang Y, Hong X, Lu Z, Song X, Song R, Yang H, et al. The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway. Oncotarget 2014; 5(18): 8478–91; PMID: 25261367
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39:493-506; PMID:20797623; http://dx.doi.org/10.1016/j.molcel.2010.07.023
   PubMed Web of Science ®Google Scholar
• Wang B, Hsu SH, Frankel W, Ghoshal K, Jacob ST. Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 α. Hepatology 2012; 56:186-97; PMID:22318941; http://dx.doi.org/10.1002/hep.25632
   PubMed Web of Science ®Google Scholar
• Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circul Res 2009; 104:1184-91; PMID:19390056; http://dx.doi.org/10.1161/CIRCRESAHA.109.197491
   PubMed Web of Science ®Google Scholar
• Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T. The role of microRNAs in human liver cancers. Semin Oncol 2011; 38:752-63; PMID:22082761; http://dx.doi.org/10.1053/j.seminoncol.2011.08.001
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature 2004; 431:350-5; PMID:15372042; http://dx.doi.org/10.1038/nature02871
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045-5
   PubMed Web of Science ®Google Scholar
• Yue J, Tigyi G. MicroRNA trafficking and human cancer. Cancer Biol Ther 2006; 5:573-8; PMID:16760647; http://dx.doi.org/10.4161/cbt.5.6.2872
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-69; PMID:16557279; http://dx.doi.org/10.1038/nrc1840
   PubMed Web of Science ®Google Scholar
• Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. New Eng J Med 2005; 353:1793-801; PMID:16251535; http://dx.doi.org/10.1056/NEJMoa050995
   PubMed Web of Science ®Google Scholar
• Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res 2005; 65:3509-12; PMID:15867338; http://dx.doi.org/10.1158/0008-5472.CAN-05-0298
   PubMed Web of Science ®Google Scholar
• He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005; 102:19075-80; PMID:16365291; http://dx.doi.org/10.1073/pnas.0509603102
   PubMed Web of Science ®Google Scholar
• Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008; 27:5643-7; PMID:18504431; http://dx.doi.org/10.1038/onc.2008.171
   PubMed Web of Science ®Google Scholar
• Zhao JL, Rao DS, Boldin MP, Taganov KD, O’Connell RM, Baltimore D. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A 2011; 108:9184-9; PMID:21576471; http://dx.doi.org/10.1073/pnas.1105398108
   PubMed Web of Science ®Google Scholar
• Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PloS One 2008; 3:e2557; PMID:18596939; http://dx.doi.org/10.1371/journal.pone.0002557
   PubMed Web of Science ®Google Scholar
• Zhu K, Pan Q, Zhang X, Kong LQ, Fan J, Dai Z, Wang L, Yang XR, Hu J, Wan JL, et al. MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis 2013; 34:2071-9; PMID:23671131; http://dx.doi.org/10.1093/carcin/bgt160
   PubMed Web of Science ®Google Scholar
• Tomokuni A, Eguchi H, Tomimaru Y, Wada H, Kawamoto K, Kobayashi S, Marubashi S, Tanemura M, Nagano H, Mori M, et al. miR-146a suppresses the sensitivity to interferon-α in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2011; 414:675-80; PMID:21982769; http://dx.doi.org/10.1016/j.bbrc.2011.09.124
   PubMed Web of Science ®Google Scholar
• Zhuo L, Liu J, Wang B, Gao M, Huang A. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013; 29:555-62; PMID:23229111
   PubMed Web of Science ®Google Scholar
• Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis and Rheumatism 2009; 60:1065-75; PMID:19333922; http://dx.doi.org/10.1002/art.24436
   PubMed Web of Science ®Google Scholar
• Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, Xu J, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011; 208:1189-201; PMID:21555486; http://dx.doi.org/10.1084/jem.20101823
   PubMed Web of Science ®Google Scholar
• Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, Spandidos DA, Libra M. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 2012; 40:1733-47; PMID:22447316
   PubMed Web of Science ®Google Scholar
• Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A. Transforming growth factor β 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A 2003; 100:4120-5; PMID:12646700; http://dx.doi.org/10.1073/pnas.0730640100
   PubMed Web of Science ®Google Scholar
• Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012; 72:1407-15; PMID:22258454; http://dx.doi.org/10.1158/0008-5472.CAN-11-2544
   PubMed Web of Science ®Google Scholar
• Quinn SR, O’Neill LA. A trio of microRNAs that control Toll-like receptor signalling. Int Immunol 2011; 23:421-5; PMID:21652514; http://dx.doi.org/10.1093/intimm/dxr034
   PubMed Web of Science ®Google Scholar
• Rusca N, Monticelli S. MiR-146a in Immunity and Disease. Mol Biol Int 2011; 2011:437301; PMID:22091404; http://dx.doi.org/10.4061/2011/437301
   PubMedGoogle Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339:286-91; PMID:23329041; http://dx.doi.org/10.1126/science.1232227
   PubMed Web of Science ®Google Scholar
• Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008; 14:417-24; PMID:18174313; http://dx.doi.org/10.1261/rna.874808
   PubMed Web of Science ®Google Scholar
• Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006; 103:12481-6; PMID:16885212; http://dx.doi.org/10.1073/pnas.0605298103
   PubMed Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11:597-610; PMID:20661255
   PubMed Web of Science ®Google Scholar
• He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447:1130-4; PMID:17554337; http://dx.doi.org/10.1038/nature05939
   PubMed Web of Science ®Google Scholar
• Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458:762-5; PMID:19219026; http://dx.doi.org/10.1038/nature07823
   PubMed Web of Science ®Google Scholar
• Rong M, He R, Dang Y, Chen G. Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Upsala J Med Sci 2014; 119:19-24; PMID:24172202; http://dx.doi.org/10.3109/03009734.2013.856970
   PubMed Web of Science ®Google Scholar
• Curtale G, Citarella F, Carissimi C, Goldoni M, Carucci N, Fulci V, Franceschini D, Meloni F, Barnaba V, Macino G. An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. Blood 2010; 115:265-73; PMID:19965651; http://dx.doi.org/10.1182/blood-2009-06-225987
   PubMed Web of Science ®Google Scholar
• Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, Yoshimura A, Baltimore D, Rudensky AY. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010; 142:914-29; PMID:20850013; http://dx.doi.org/10.1016/j.cell.2010.08.012
   PubMed Web of Science ®Google Scholar
• Li Y, Shi X. MicroRNAs in the regulation of TLR and RIG-I pathways. Cell Mol Immunol 2013; 10:65-71; PMID:23262976; http://dx.doi.org/10.1038/cmi.2012.55
   PubMed Web of Science ®Google Scholar
• Xiao B, Zhu ED, Li N, Lu DS, Li W, Li BS, Zhao YL, Mao XH, Guo G, Yu PW, et al. Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. Oncol Rep 2012; 27:559-66; PMID:22020746
   PubMed Web of Science ®Google Scholar
• Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A 2003; 100:4138-43; PMID:12640143; http://dx.doi.org/10.1073/pnas.0534764100
   PubMed Web of Science ®Google Scholar